Confidentiality Orders and Public Interest in Drug and Medical Device Litigation

Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. Howeve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of internal medicine (1960) 2020-02, Vol.180 (2), p.292-299
Hauptverfasser: Egilman, Alexander C, Kesselheim, Aaron S, Krumholz, Harlan M, Ross, Joseph S, Kim, Jeanie, Kapczynski, Amy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 299
container_issue 2
container_start_page 292
container_title Archives of internal medicine (1960)
container_volume 180
creator Egilman, Alexander C
Kesselheim, Aaron S
Krumholz, Harlan M
Ross, Joseph S
Kim, Jeanie
Kapczynski, Amy
description Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. However, in practice, courts and litigants commonly use overly broad or unwarranted confidentiality orders, which can prevent the public from accessing important public health information that emerges during litigation. This Special Communication reviews the rules governing confidentiality orders and discusses the tension between these rules and prevailing legal practices relating to court secrecy in medical product litigation, including competing interests among manufacturers, plaintiffs, and courts. Using examples of successful efforts to challenge confidentiality orders, we describe how these prevailing legal practices can undermine access to information by patients, clinicians, and the US Food and Drug Administration and also obscure patterns of injury and disease associated with the drugs and medical devices at issue. We then discuss several ways to advance access to information important to public health that emerges during litigation, focusing particularly on the role of medical experts engaged in cases.
doi_str_mv 10.1001/jamainternmed.2019.5161
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2309807409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2753427</ama_id><sourcerecordid>2309807409</sourcerecordid><originalsourceid>FETCH-LOGICAL-a337t-582fdf254f9f9ff5c2c4d7595e272753086fc3d6630b36a12cdf993bfda9ec753</originalsourceid><addsrcrecordid>eNpdkEtLAzEUhYMoWLR_wI0BN26m5jGTTJbS-ihU2oWuQ5pHSZlmajIj9N-bsVLQm8W9cL9zuDkA3GI0wQjhh63aKR86G8POmglBWEwqzPAZGBHM6oJhXJ6fZsQuwTilLcpVI1RSOgKraRucNzZ0XjW-O8BlNDYmqIKBq37deA3ng79NHfQBzmK_-dm9WeO1auDMfnlt4cJ3fqM634ZrcOFUk-z4t1-Bj-en9-lrsVi-zKePi0JRyruiqokzjlSlE_m5ShNdGl6JyhJOeEVRzZymhjGK1pQpTLRxQtC1M0pYnYErcH_03cf2s8_nyZ1P2jaNCrbtkyQUiRrxEomM3v1Dt20fQ74uU4zXZUnwYMiPlI5tStE6uY9-p-JBYiSHsOWfsOUQthzCzsqbozLvT6LhEyXh9BuPKX5A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2367844215</pqid></control><display><type>article</type><title>Confidentiality Orders and Public Interest in Drug and Medical Device Litigation</title><source>American Medical Association Journals</source><creator>Egilman, Alexander C ; Kesselheim, Aaron S ; Krumholz, Harlan M ; Ross, Joseph S ; Kim, Jeanie ; Kapczynski, Amy</creator><creatorcontrib>Egilman, Alexander C ; Kesselheim, Aaron S ; Krumholz, Harlan M ; Ross, Joseph S ; Kim, Jeanie ; Kapczynski, Amy</creatorcontrib><description>Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. However, in practice, courts and litigants commonly use overly broad or unwarranted confidentiality orders, which can prevent the public from accessing important public health information that emerges during litigation. This Special Communication reviews the rules governing confidentiality orders and discusses the tension between these rules and prevailing legal practices relating to court secrecy in medical product litigation, including competing interests among manufacturers, plaintiffs, and courts. Using examples of successful efforts to challenge confidentiality orders, we describe how these prevailing legal practices can undermine access to information by patients, clinicians, and the US Food and Drug Administration and also obscure patterns of injury and disease associated with the drugs and medical devices at issue. We then discuss several ways to advance access to information important to public health that emerges during litigation, focusing particularly on the role of medical experts engaged in cases.</description><identifier>ISSN: 2168-6106</identifier><identifier>EISSN: 2168-6114</identifier><identifier>DOI: 10.1001/jamainternmed.2019.5161</identifier><language>eng</language><publisher>Chicago: American Medical Association</publisher><subject>Confidentiality ; Litigation ; Pharmaceutical industry ; Public interest</subject><ispartof>Archives of internal medicine (1960), 2020-02, Vol.180 (2), p.292-299</ispartof><rights>Copyright American Medical Association Feb 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a337t-582fdf254f9f9ff5c2c4d7595e272753086fc3d6630b36a12cdf993bfda9ec753</citedby><cites>FETCH-LOGICAL-a337t-582fdf254f9f9ff5c2c4d7595e272753086fc3d6630b36a12cdf993bfda9ec753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamainternalmedicine/articlepdf/10.1001/jamainternmed.2019.5161$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2019.5161$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,776,780,3327,27901,27902,76231,76234</link.rule.ids></links><search><creatorcontrib>Egilman, Alexander C</creatorcontrib><creatorcontrib>Kesselheim, Aaron S</creatorcontrib><creatorcontrib>Krumholz, Harlan M</creatorcontrib><creatorcontrib>Ross, Joseph S</creatorcontrib><creatorcontrib>Kim, Jeanie</creatorcontrib><creatorcontrib>Kapczynski, Amy</creatorcontrib><title>Confidentiality Orders and Public Interest in Drug and Medical Device Litigation</title><title>Archives of internal medicine (1960)</title><description>Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. However, in practice, courts and litigants commonly use overly broad or unwarranted confidentiality orders, which can prevent the public from accessing important public health information that emerges during litigation. This Special Communication reviews the rules governing confidentiality orders and discusses the tension between these rules and prevailing legal practices relating to court secrecy in medical product litigation, including competing interests among manufacturers, plaintiffs, and courts. Using examples of successful efforts to challenge confidentiality orders, we describe how these prevailing legal practices can undermine access to information by patients, clinicians, and the US Food and Drug Administration and also obscure patterns of injury and disease associated with the drugs and medical devices at issue. We then discuss several ways to advance access to information important to public health that emerges during litigation, focusing particularly on the role of medical experts engaged in cases.</description><subject>Confidentiality</subject><subject>Litigation</subject><subject>Pharmaceutical industry</subject><subject>Public interest</subject><issn>2168-6106</issn><issn>2168-6114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkEtLAzEUhYMoWLR_wI0BN26m5jGTTJbS-ihU2oWuQ5pHSZlmajIj9N-bsVLQm8W9cL9zuDkA3GI0wQjhh63aKR86G8POmglBWEwqzPAZGBHM6oJhXJ6fZsQuwTilLcpVI1RSOgKraRucNzZ0XjW-O8BlNDYmqIKBq37deA3ng79NHfQBzmK_-dm9WeO1auDMfnlt4cJ3fqM634ZrcOFUk-z4t1-Bj-en9-lrsVi-zKePi0JRyruiqokzjlSlE_m5ShNdGl6JyhJOeEVRzZymhjGK1pQpTLRxQtC1M0pYnYErcH_03cf2s8_nyZ1P2jaNCrbtkyQUiRrxEomM3v1Dt20fQ74uU4zXZUnwYMiPlI5tStE6uY9-p-JBYiSHsOWfsOUQthzCzsqbozLvT6LhEyXh9BuPKX5A</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Egilman, Alexander C</creator><creator>Kesselheim, Aaron S</creator><creator>Krumholz, Harlan M</creator><creator>Ross, Joseph S</creator><creator>Kim, Jeanie</creator><creator>Kapczynski, Amy</creator><general>American Medical Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20200201</creationdate><title>Confidentiality Orders and Public Interest in Drug and Medical Device Litigation</title><author>Egilman, Alexander C ; Kesselheim, Aaron S ; Krumholz, Harlan M ; Ross, Joseph S ; Kim, Jeanie ; Kapczynski, Amy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a337t-582fdf254f9f9ff5c2c4d7595e272753086fc3d6630b36a12cdf993bfda9ec753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Confidentiality</topic><topic>Litigation</topic><topic>Pharmaceutical industry</topic><topic>Public interest</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Egilman, Alexander C</creatorcontrib><creatorcontrib>Kesselheim, Aaron S</creatorcontrib><creatorcontrib>Krumholz, Harlan M</creatorcontrib><creatorcontrib>Ross, Joseph S</creatorcontrib><creatorcontrib>Kim, Jeanie</creatorcontrib><creatorcontrib>Kapczynski, Amy</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of internal medicine (1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Egilman, Alexander C</au><au>Kesselheim, Aaron S</au><au>Krumholz, Harlan M</au><au>Ross, Joseph S</au><au>Kim, Jeanie</au><au>Kapczynski, Amy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Confidentiality Orders and Public Interest in Drug and Medical Device Litigation</atitle><jtitle>Archives of internal medicine (1960)</jtitle><date>2020-02-01</date><risdate>2020</risdate><volume>180</volume><issue>2</issue><spage>292</spage><epage>299</epage><pages>292-299</pages><issn>2168-6106</issn><eissn>2168-6114</eissn><abstract>Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. However, in practice, courts and litigants commonly use overly broad or unwarranted confidentiality orders, which can prevent the public from accessing important public health information that emerges during litigation. This Special Communication reviews the rules governing confidentiality orders and discusses the tension between these rules and prevailing legal practices relating to court secrecy in medical product litigation, including competing interests among manufacturers, plaintiffs, and courts. Using examples of successful efforts to challenge confidentiality orders, we describe how these prevailing legal practices can undermine access to information by patients, clinicians, and the US Food and Drug Administration and also obscure patterns of injury and disease associated with the drugs and medical devices at issue. We then discuss several ways to advance access to information important to public health that emerges during litigation, focusing particularly on the role of medical experts engaged in cases.</abstract><cop>Chicago</cop><pub>American Medical Association</pub><doi>10.1001/jamainternmed.2019.5161</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2168-6106
ispartof Archives of internal medicine (1960), 2020-02, Vol.180 (2), p.292-299
issn 2168-6106
2168-6114
language eng
recordid cdi_proquest_miscellaneous_2309807409
source American Medical Association Journals
subjects Confidentiality
Litigation
Pharmaceutical industry
Public interest
title Confidentiality Orders and Public Interest in Drug and Medical Device Litigation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T17%3A05%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Confidentiality%20Orders%20and%20Public%20Interest%20in%20Drug%20and%20Medical%20Device%20Litigation&rft.jtitle=Archives%20of%20internal%20medicine%20(1960)&rft.au=Egilman,%20Alexander%20C&rft.date=2020-02-01&rft.volume=180&rft.issue=2&rft.spage=292&rft.epage=299&rft.pages=292-299&rft.issn=2168-6106&rft.eissn=2168-6114&rft_id=info:doi/10.1001/jamainternmed.2019.5161&rft_dat=%3Cproquest_cross%3E2309807409%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2367844215&rft_id=info:pmid/&rft_ama_id=2753427&rfr_iscdi=true